Axogen Stock News

Exchange Traded Concepts LLC lifted its position in AxoGen, Inc. (NASDAQ:AXGN) by 21.5% in the third quarter, Holdings Channel.com reports. The institutional investor owned 206,695 shares of the medical equipment providers stock after buying an additional 36,566 shares during the period. Exchange Traded Concepts LLCs holdings in AxoGen were worth $3,266,000 at the end of []

The Nerve Conduit Market report is a valuable source of insightful data for business strategists. It provides the industry overview with growth analysis and historical & futuristic cost, revenue, demand, and supply data (as applicable). The research analysts provide an

Axogen Inc. (AXGN) shares closed today at 0.9% above its 52 week low of $9.50, giving the company a market cap of $398M. The stock is currently down 46.4% year-to-date, down 32.8% over the past 12 months, and up 9.0% over the past five years. This week, the Dow Jones Industrial Average fell 1.9%, and the S&P 500 fell 2.1%. Trading Activity Trading volume this week was 41.2% higher than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.8. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -440.8% The company's stock price performance over the past 12 months lags the peer average by -270.6% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

AxoGen Inc. (NASDAQ:AXGN)s traded shares stood at 0.61 million during the last session, with the companys beta value hitting 0.72. At the close of trading, the stocks price was $9.76, to imply a decrease of -3.65% or -$0.37 in intraday trading. The AXGN shares 52-week high remains $23.94, putting it -145.29% down since that peak AxoGen Inc. (NASDAQ: AXGN) Loss Of -3.18% Compared To 52-Week Low; YTD Fall -45.47% What Should You Do Now? Read More »

AxoGen's (AXGN) CEO Karen Zaderej on Q3 2021 Results - Earnings Call Transcript

AxoGen (AXGN) delivered earnings and revenue surprises of 25.00% and -9.95%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Axogen (NASDAQ:AXGN) reported its Q3 earnings results on Wednesday, November 3, 2021 at 04:00 PM. Here's what investors need to know about the announcement.

ALACHUA, Fla. and TAMPA, Fla., Oct. 13, 2021 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to per

RECON is a pivotal study supporting the Company's Biologics License Application (BLA) for Avance® Nerve Graft RECON is a pivotal study supporting the Company's Biologics License Application (BLA) for

Axogen continues posting double-digit growth in volumes against 2019 levels despite trauma, breast recon, and oral-maxillofacial procedures still well below pre-pandemic levels.

AxoGen's (AXGN) CEO Karen Zaderej on Q2 2021 Results - Earnings Call Transcript

AxoGen (AXGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Global leader brings 30+ years of biopharma experience to Axogen, Inc. Board of Directors Global leader brings 30+ years of biopharma experience to Axogen, Inc. Board of Directors

ALACHUA, Fla. and TAMPA, Fla., July 14, 2021 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to per

ALACHUA, Fla. and TAMPA, Fla., May 18, 2021 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or discontinuity to pe